表紙
市場調査レポート

次世代血糖コントロール薬

Next-Generation Glycemic Control Therapeutics

発行 Greystone Research Associates 商品コード 337816
出版日 ページ情報 英文
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.95円で換算しております。
Back to Top
次世代血糖コントロール薬 Next-Generation Glycemic Control Therapeutics
出版日: 2015年08月24日 ページ情報: 英文
概要

糖尿病の患者数が世界的に増加を続けるなかで、薬剤開発者および研究者は、特に2型向けに血糖値をコントロールするより効果的な方法を模索しています。これらの取り組みから、承認済みあるいは後期開発段階のGLP-1アゴニストおよびDPP-4阻害剤のリストが拡充され、また、新しい医薬成分の薬剤や独自の潜在的メリットを持つ薬剤が関心を集め、研究への投資対象となっています。

当レポートでは、次世代血糖コントロール薬の市場について調査し、承認済み薬剤の種類と概要、承認済み薬剤の世界市場の規模、投薬および処方に関する動向と課題、開発後期段階の製品の種類と概要、関連法規制とその課題、市場成長への影響因子の分析、競合環境、主要事業者のプロファイルなどをまとめています。

エグゼクティブサマリー

市場機会

  • 血糖コントロール市場の力学
  • 市場区分
  • 市場成長推進因子
  • 人口構成の変化
  • 薬剤需要の推進因子
  • 競合環境
  • リスク因子

承認済み次世代治療薬

  • 吸入型インスリン
  • GLP-1アゴニスト
  • アミリンアナログ
  • DPP-4阻害剤
  • ナトリウムグルコース共輸送体2 (SGLT2) 阻害剤

開発段階の血糖コントロール製品

  • インスリン
  • 吸入型インスリン
  • GLP-1アゴニスト
  • DPP-4阻害剤
  • SGLT2阻害剤
  • 2剤併用薬
  • 新しいMOA
    • PPAR
    • グルカゴン受容体拮抗薬

市場データ・予測

市場影響因子

  • 法規制上の課題
  • 患者による服薬コンプライアンス・利用の容易さ
  • 医療経済学
  • 地域的な市場影響因子

企業プロファイル

目次
Product Code: GCT494R

The Promise of New Drug Classes & MOAs

As the number of patients diagnosed with diabetes continues to climb worldwide, drug developers and researchers are attempting for find more effective ways to control glucose levels, particularly for Type 2 diabetics. These efforts have led to a growing list of GLP-1 agonists and DPP-4 inhibitors that have been approved or are in late stage clinical development. New medicines based on novel therapeutic moieties and potentially unique benefits are attracting attention and research investment. The result is an evolving therapeutic landscape that is providing clinicians and patients with new ways to manage their diabetes. For market participants, product positioning and prescriber training will become increasingly important as competitive threats remain fluid.

The value we provide to our clients and subscribers is best illustrated by our ability to consistently provide strategic direction and market knowledge that contributes to their tactical and strategic decision process.

Market-driven Product Strategies

A longer life span is expected to translate to a growing number of patients diagnosed with chronic conditions. To counteract the financial and medical infrastructure implications of this trend, pressure from the public sector and managed care organizations will place a premium on therapeutic self-administration, an expectation that is creating an increased interest in routes of administration that are patient-friendly and cost-effective. Pharma company decision makers have come to the realization that for many products, success no longer only depends on the medication itself but also on achieving a consumer-compatible form of packaging and application.

The market for glycemic control continues to grow globally at rates that are alarming to public health officials. Over the past decade, prevalence of diabetes among adults has increased by 33 percent. In the United States, approximately 6 percent of the population (i.e., 16 million people) has diabetes and it is the fourth-leading cause of death by disease. Among Americans in their thirties, diabetes has increased by 70 percent in the past 10 years. Each year, approximately 798,000 people are diagnosed with diabetes. However, one-third of the people afflicted are currently undiagnosed.

Our reports are carefully researched and written to provide timely and insightful analysis of key factors and developments shaping the commercial marketplace. The focused nature of our publications is designed to allow readers to identify emerging demand and growth opportunities in selected markets. Numerous charts, tables and graphs complement the text, with evaluations and assessments of current and probable future market developments, technology issues and business factors - information necessary to compete effectively in the global marketplace.

What You Will Learn

  • What therapeutic drugs are currently marketed for glycemic control, how are they administered, who markets them, and what is the size of the global market?
  • What are the important factors in patient self-administration of glycemic drugs, what are the current prescribing trends, and what are the key factors influencing demand?
  • What are the regional factors affecting market size and demand?
  • What are the new classes of drugs that are entering the market for treating diabetes, what is their market share and what are their growth prospects?
  • What drugs are expected to enter the market in the next five years, and what will be their probable impact on the overall market?
  • What are the significant economic, technology, and regulatory factors affecting the market for glycemic control therapeutics?

Table of Contents

  • Executive SummaryThe Market Opportunity
  • Glycemic Control Market Dynamics
  • Market Segments
  • What's Driving the Market?
  • Shifting Demographics
  • Therapeutic Demand Drivers
  • Competitive Landscape
  • Risk Factors
  • Approved Next-Generation Therapeutics
  • Inhaled Insulin
  • GLP-1 Agonists
  • Amylin Analogs
  • DPP-4 Inhibitors
  • Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitors
  • Development-stage Glycemic Control Products
  • Insulins
  • Inhaled Insulin
  • GLP-1 Agonists
  • DPP-4 Inhibitors
  • SGLT2 Inhibitors
  • Dual Therapy Drugs
  • New MOAs
  • PPARs
  • Glucagon Receptor Antagonist
  • Market Data and Forecasts
  • Market Factors
  • Regulatory Issues
  • Patient Compliance and Ease of Use
  • Healthcare Economics
  • Regional Market Factors
  • Company Profiles
Back to Top